



PFA in APAC,

from Promise
to Practice



Electrophysiologists (EPs) across Asia Pacific (APAC) see pulsed field ablation (PFA) as a transformative advancement in atrial fibrillation (AFib) care, with broader adoption expected to accelerate in the coming years.

As clinical confidence grows, there is a clear opportunity to strengthen referral pathways, patient engagement, system readiness and collaboration across the care continuum to improve the quality and equity of AFib care across the region.

Looking ahead, EPs envision a future where PFA innovation enables earlier AFib intervention, expands ablation options and ensures better clinical outcomes and quality of life for more patients.

Insight 1 EPs recognize the clinical value of PFA



71%
Said PFA offers shorter procedure duration



63%
Observed higher patient satisfaction




56%
Described the learning curve as easier than other ablation approaches


What does this mean?

PFA's value is increasingly reflected in clinical practice. EPs associate PFA with procedural efficiency, procedural confidence and positive patient experiences, reinforcing its potential role in future rhythm-control strategies.


Insight 2 Despite strong clinical recognition, PFA adoption remains inconsistent due to multifaceted barriers



Reported fewer than half of eligible patients are referred within one year of diagnosis



Said patient fear or limited AFib understanding delays treatment decisions



Cited limited financial support or reimbursement as a barrier for some patients

What does this mean?

Strong clinician confidence in PFA is not yet consistently reflected in routine practice. Opportunities remain to strengthen referral pathways, patient engagement, system readiness and access to help more patients benefit from innovation.

Insight 3 EPs identified four key enablers needed to support broader and more confident PFA adoption



74% Highlighted long-term efficacy and durability evidence as a key enabler



71% Said referral pathway optimization would improve access and uptake



62% Called for stronger collaboration across clinicians, healthcare systems and industry




55% Emphasized guideline implementation as an important driver of adoption

What does this mean?

Successful integration of PFA depends not only on technology but also on evidence generation, care pathway optimization, education, collaboration and supportive healthcare systems.

Insight 4 EPs envisioned a future where PFA plays a more prominent role in AFib patient management



92%

Expect PFA to become their preferred ablation modality within two years



64%

Project increased first-line ablation use for paroxysmal AFib



61%

Anticipate broader application in persistent AFib



57%


Foresee earlier intervention in asymptomatic or early-stage AFib

What does this mean?

EPs envision a future where innovation supports earlier intervention, broader treatment options and more proactive management of AFib across the patient journey.

Five priorities for collective action, co-created with EPs

1



Shift AFib care from reactive treatment to earlier and proactive multidisciplinary care

Support earlier and wider use of rhythm-control strategies and ablation where appropriate, helping patients access specialist care and intervention before disease progression.

2



Strengthen guideline implementation and workflow integration within existing care pathways

Promote consistent understanding and application across the AFib care and ablation pathway.

3



Improve awareness, health literacy and patient empowerment

Support informed discussions and shared decision-making so patients can engage confidently in their care journey.


4



Enable and support timely and equitable access

Advance access frameworks that recognize clinical outcomes, patient experience and broader healthcare system value.

5



Strengthen end-to-end collaboration with EPs in informing medical technology innovators

Deepen collaboration between EPs and innovators to ensure future technologies remain aligned with real-world clinical needs.

About the report



This infographic is based on findings from the report, PFA in APAC, from Promise to Practice, which captures EP perspectives on the evolving role of PFA in AFib care. Commissioned by Boston Scientific and informed by regional survey data, EP interviews and existing literature, the report explores clinician experiences, perspectives and future visions for PFA, highlighting its clinical value, implementation challenges, key enablers for broader adoption and opportunities to advance patient care across the region.

Access the full [PFA in APAC, from Promise to Practice](#) report.

The content in the report is provided for healthcare professionals only.

Certain indications or procedures referenced may not be approved, licensed, or available in all countries or regions. Regulatory status, approved indications, and availability vary by country, and viewers should consult local approved product labeling, instructions for use, and applicable regulatory approvals.

Healthcare professionals must exercise their own independent clinical judgment when evaluating patients and selecting treatment options. Boston Scientific does not promote or encourage the use of its devices outside their approved labeling or local regulatory approvals. No content on this channel should be interpreted as an endorsement of any specific treatment approach for any individual patient.

References to third-party publications are provided for informational purposes only and do not imply endorsement by Boston Scientific. While reasonable efforts have been made to accurately present information from cited third-party sources, the accuracy and currency of such materials remain the responsibility of their respective authors and/or publishers.

A total of 137 EPs participated in a double-blinded survey, and five EPs participated in individual non-blinded interviews.